Efficacy and Safety of Radiotherapy Combined with Chemoimmunotherapy vs. Chemoimmunotherapy Alone as First-Line Treatment for Advanced Esophageal Squamous Cell Carcinoma with Oligorecurrence

被引：0
|
作者：
Lv, X. [1 ]
Wang, Y. [1 ]
Ai, J. [1 ]
Wang, Q. [1 ]
Wang, J. [2 ]
机构：
[1] Hebei Med Univ, Hosp 4, Shijiazhuang, Hebei, Peoples R China
[2] Hebei Med Univ, Hosp 4, Dept Radiat Oncol, Shijiazhuang, Hebei, Peoples R China
来源：
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2024年 / 120卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3089
引用
收藏
页码：E493 / E493
页数：1
相关论文
共 50 条
  • [31] Cost-effectiveness analysis of serplulimab as first-line treatment for advanced esophageal squamous cell carcinoma
    Zheng, Zhiwei
    Fang, Ling
    Cai, Hongfu
    Zhu, Huide
    IMMUNOTHERAPY, 2023, 15 (13) : 1045 - 1055
  • [32] Complete response of advanced esophageal squamous cell carcinoma with first-line chemotherapy combined with immunotherapy: a Case report
    Wei, Yahong
    Han, Shaohui
    Shi, Yabin
    Li, Yaxing
    Zhang, Qi
    Zhang, Lijuan
    Cheng, Yan
    Yan, Xiaolu
    Jia, Yitao
    FRONTIERS IN IMMUNOLOGY, 2025, 16
  • [33] Assessment of durable chemoimmunotherapy response via circulating tumor DNA in advanced esophageal squamous cell carcinoma
    Yang, Dongyang
    Xu, Fei
    Li, Ying
    Lai, Xiaorong
    Xian, Bohong
    Yu, Pengli
    Chen, Rongrong
    Li, Zijun
    Ma, Dong
    THORACIC CANCER, 2022, 13 (19) : 2786 - 2791
  • [34] Efficacy and safety of SHR-1210 combined with apatinib in first-line treatment for advanced lung squamous cell carcinoma: A phase II study.
    Wang, Jinliang
    Zhang, Zhibo
    Yan, Xiang
    Ma, Junxun
    Zhang, Fan
    Song, Qi
    Zhang, Li
    Liu, Zhefeng
    Yang, Bo
    Wang, Lijie
    Tao, Haitao
    Zhang, Sujie
    Li, Xiaoyan
    Hu, Jie
    Li, Xiaoting
    Wang, Jiaqian
    Zhi, Xiaoyu
    Ge, Xiangwei
    Jiao, Shunchang
    Hu, Yi
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [35] Safety and tolerability of first-line durvalumab with tremelimumab and chemotherapy in esophageal squamous cell carcinoma
    Lee, Dae Ho
    Kim, Hye Ryun
    Keam, Bhumsuk
    Kato, Ken
    Kuboki, Yasutoshi
    Gao, Haiyan
    Yovine, Alejandro
    Robbins, Scott H. H.
    Ahn, Myung-Ju
    CANCER MEDICINE, 2023, 12 (15): : 16066 - 16075
  • [36] Phase II clinical trial using camrelizumab combined with apatinib and chemotherapy as the first-line treatment of advanced esophageal squamous cell carcinoma
    Zhang, Bo
    Qi, Ling
    Wang, Xi
    Xu, Jianping
    Liu, Yun
    Mu, Lan
    Wang, Xingyuan
    Bai, Lidan
    Huang, Jing
    CANCER COMMUNICATIONS, 2020, 40 (12) : 711 - 720
  • [37] Recombinant human-endostatin combined with sintilimab and chemotherapy in first-line treatment of locally advanced or metastatic esophageal squamous cell carcinoma
    Cui, Shiyun
    Fan, Lei
    Sun, Xinnan
    Cai, Yucheng
    Wang, Ting
    Li, Ping
    Wang, Rong
    Liu, Lianke
    ONCOLOGY LETTERS, 2025, 29 (05)
  • [38] Efficacy and safety of camrelizumab combined with chemotherapy as second-line treatment for locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma
    Gu, Yinfang
    Zou, Xiaofang
    Zhu, Junlin
    Wu, Guowu
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2025, 23 (01)
  • [39] Survival Comparision of Three-dimensional Radiotherapy Alone vs. Chemoradiotherapy for Esophageal Squamous Cell Carcinoma
    Zhang, An-Du
    Su, Xiao-Hua
    Shi, Gao-Feng
    Han, Chun
    Wang, Lan
    Liu, Hui
    Zhang, Jun
    Zhang, Ruo-Hui
    ARCHIVES OF MEDICAL RESEARCH, 2020, 51 (05) : 419 - 428
  • [40] New first-line treatment strategies for advanced lung squamous cell carcinoma
    Cai, Xiuyu
    Yu, Hui
    Cai, Yanyu
    Zhang, Bei
    Zhou, Yixin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2020, 9 (02) : 414 - 417
12345